Supernus Pharmaceuticals, Inc. (SUPN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-07

Key Insights

  • Supernus Pharmaceuticals has agreed to acquire the assets related to the compound NV-5138 or SPN-820 from Navitor Pharmaceuticals through an asset purchase agreement.
  • The agreement includes milestone payments of up to $350 million contingent upon the achievement of specified development, regulatory and commercial milestones for the acquired compound.
  • The company has the right to discontinue the development of the compound after the completion of the Phase 2b study if it determines the study was not successful.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Supernus Pharmaceuticals, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.